Sandoz Files US Trastuzumab With EirGenix

Five Separate Herceptin Biosimilars Are Already Competing In US Market

 
• By Dave Wallace

Sandoz has filed the proposed trastuzumab biosimilar developed by partner EirGenix with the US FDA. If approved, the product will have to compete in an already busy market for Herceptin biosimilars.

Red Wooden Figure Stand Out In Crowd
Sandoz will be seeking to stand out among trastuzumab competitors • Source: designer491 / Alamy Stock Photo

More from Biosimilars

More from Products